Drug intelligence / Profile preview

DBV712 IHRP

Development stage: Unknown
Lead developer: DBV Technologies
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Topical

Overview

DBV712 IHRP is an In-House Reference Preparation (IHRP) of peanut allergen extract, developed by DBV Technologies. It is formulated as a solution specifically for use in Skin Prick Tests (SPT). Its primary purpose is to assess the biological potency of peanut allergens in peanut-allergic subjects, serving as a reference standard for the allergen content related to the therapeutic epicutaneous immunotherapy patch, DBV712 (Viaskin Peanut).

Beyond the preview

Go deeper on DBV712 IHRP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBV712 IHRP.

Explore the full profile